Cholinergic enhancement of brain activation in mild cognitive impairment during episodic memory encoding

Frontiers in Psychiatry

Volumn 4, Issue SEP, 2013, Pages

  Risacher, Shannon L ^a   Wang, Yang ^a   Wishart, Heather A ^b   Rabin, Laura A ^c   Flashman, Laura A ^b   McDonald, Brenna C ^a,b   West, John D ^a   Santulli, Robert B ^b   Saykin, Andrew J ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Alzheimer's disease; Donepezil (Aricept); Episodic encoding; Functional magnetic resonance imaging; Mild cognitive impairment; Task related functional connectivity

Indexed keywords

DONEPEZIL;

AGED; ANTERIOR CINGULATE; ARTICLE; BRAIN FUNCTION; BRAIN STEM; CAUDATE NUCLEUS; CEREBELLUM; CLAUSTRUM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG DOSE INCREASE; EPISODIC MEMORY; FEMALE; FRONTAL LOBE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL SYMPTOM; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; INFERIOR PARIETAL LOBULE; INSULA; LEG CRAMP; MALE; MENTAL PERFORMANCE; MIDDLE FRONTAL GYRUS; MILD COGNITIVE IMPAIRMENT; PARAHIPPOCAMPAL GYRUS; POSTCENTRAL GYRUS; POSTERIOR CINGULATE; PRECUNEUS; PRIMARY MOTOR CORTEX; PUTAMEN; SLEEP DISORDER; SUBTHALAMIC NUCLEUS; SUPERIOR FRONTAL GYRUS; SUPERIOR PARIETAL LOBULE; SUPERIOR TEMPORAL GYRUS; TASK PERFORMANCE; THALAMUS; TREATMENT DURATION; UNCUS;

EID: 84885367864     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00105     Document Type: Article

References (65)

1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement (2011) 7:208-44. doi:10.1016/j.jalz.2011.02.004.
2. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 7:270-9. doi:10.1016/j.jalz.2011.03.008.
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 56:303-8. doi:10.1001/archneur.56.3.303.
4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 7:263-9. doi:10.1016/j.jalz.2011.03.005.
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev (2006):CD005593.
6. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev (2012) 9:CD009132. doi:10.1002/14651858.CD009132.pub2.
7. Mattay VS, Callicott JH, Bertolino A, Heaton I, Frank JA, Coppola R, et al. Effects of dextroamphetamine on cognitive performance and cortical activation. Neuroimage (2000) 12:268-75. doi:10.1006/nimg.2000.0610.
8. Thiel CM, Henson RN, Morris JS, Friston KJ, Dolan RJ. Pharmacological modulation of behavioral and neuronal correlates of repetition priming. J Neurosci (2001) 21:6846-52.
9. Sperling R, Greve D, Dale A, Killiany R, Holmes J, Rosas HD, et al. Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci U S A (2002) 99:455-60. doi:10.1073/pnas.012467899.
10. Dickerson BC. Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment. Curr Opin Psychiatry (2006) 19:299-306. doi:10.1097/01.yco.0000218602.25346.c6.
11. Dumas JA, Saykin AJ, McDonald BC, McAllister TW, Hynes ML, Newhouse PA. Nicotinic versus muscarinic blockade alters verbal working memory-related brain activity in older women. Am J Geriatr Psychiatry (2008) 16:272-82. doi:10.1097/JGP.0b013e3181602a2b.
12. Dumas JA, McDonald BC, Saykin AJ, McAllister TW, Hynes ML, West JD, et al. Cholinergic modulation of hippocampal activity during episodic memory encoding in postmenopausal women: a pilot study. Menopause (2010) 17:852-9. doi:10.1097/gme.0b013e3181e04db9.
13. McAllister TW, Flashman LA, McDonald BC, Ferrell RB, Tosteson TD, Yanofsky NN, et al. Dopaminergic challenge with bromocriptine one month after mild traumatic brain injury: altered working memory and BOLD response. J Neuropsychiatry Clin Neurosci (2011) 23:277-86. doi:10.1176/appi.neuropsych.23.3.277.
14. McAllister TW, McDonald BC, Flashman LA, Ferrell RB, Tosteson TD, Yanofsky NN, et al. Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response. Int J Psychophysiol (2011) 82:107-14. doi:10.1016/j.ijpsycho.2011.06.022.
15. Rombouts SA, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2002) 73:665-71. doi:10.1136/jnnp.73.6.665.
16. Goekoop R, Rombouts SA, Jonker C, Hibbel A, Knol DL, Truyen L, et al. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. Neuroimage (2004) 23:1450-9. doi:10.1016/j.neuroimage.2004.08.006.
17. Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain (2004) 127:1574-83. doi:10.1093/brain/awh177.
18. Kircher TT, Erb M, Grodd W, Leube DT. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. Am J Geriatr Psychiatry (2005) 13:1006-13. doi:10.1176/appi.ajgp.13.11.1006.
19. Goekoop R, Scheltens P, Barkhof F, Rombouts SA. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation-a pharmacological fMRI study. Brain (2006) 129:141-57. doi:10.1093/brain/awh671.
20. Gron G, Brandenburg I, Wunderlich AP, Riepe MW. Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging (2006) 27:78-87. doi:10.1016/j.neurobiolaging.2004.12.005.
21. Shanks MF, McGeown WJ, Forbes-Mckay KE, Waiter GD, Ries M, Venneri A. Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease. Magn Reson Imaging (2007) 25:848-59. doi:10.1016/j.mri.2007.02.005.
22. Bentley P, Driver J, Dolan RJ. Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. Brain (2008) 131:409-24. doi:10.1093/brain/awm299.
23. Bokde AL, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, et al. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. J Clin Psychopharmacol (2009) 29:147-56. doi:10.1097/JCP.0b013e31819a8f2e.
24. Petrella JR, Prince SE, Krishnan S, Husn H, Kelley L, Doraiswamy PM. Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. AJNR Am J Neuroradiol (2009) 30:411-6. doi:10.3174/ajnr. A1359.
25. Venneri A, McGeown WJ, Shanks MF. Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation. Curr Alzheimer Res (2009) 6:97-111. doi:10.2174/156720509787602933.
26. McGeown WJ, Shanks MF, Forbes-Mckay KE, Waiter GD, Elrick I, Venneri MG, et al. Established donepezil treatment modulates task relevant regional brain activation in early Alzheimer's disease. Curr Alzheimer Res (2010) 7:415-27. doi:10.2174/156720510791383877.
27. Thiyagesh SN, Farrow TF, Parks RW, Accosta-Mesa H, Hunter MD, Young C, et al. Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study. Dement Geriatr Cogn Disord (2010) 29:176-88. doi:10.1159/000275674.
28. Goveas JS, Xie C, Ward BD, Wu Z, Li W, Franczak M, et al. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. J Magn Reson Imaging (2011) 34:764-73. doi:10.1002/jmri.22662.
29. Miettinen PS, Pihlajamaki M, Jauhiainen AM, Tarkka IM, Grohn H, Niskanen E, et al. Effect of cholinergic stimulation in early Alzheimer's disease-functional imaging during a recognition memory task. Curr Alzheimer Res (2011) 8:753-64. doi:10.2174/156720511797633241.
30. Li W, Antuono PG, Xie C, Chen G, Jones JL, Ward BD, et al. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment. Neuroimage (2012) 60:1083-91. doi:10.1016/j.neuroimage.2011.12.077.
31. McLaren DG, Sreenivasan A, Diamond EL, Mitchell MB, Van Dijk KR, Deluca AN, et al. Tracking cognitive change over 24 weeks with longitudinal functional magnetic resonance imaging in Alzheimer's disease. Neurodegener Dis (2012) 9:176-86. doi:10.1159/000335876.
32. Pa J, Berry AS, Compagnone M, Boccanfuso J, Greenhouse I, Rubens MT, et al. Cholinergic enhancement of functional networks in older adults with MCI. Ann Neurol (2013) 73:762-73. doi:10.1002/ana.23874.
33. Sole-Padulles C, Bartres-Faz D, Llado A, Bosch B, Pena-Gomez C, Castellvi M, et al. Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease. J Clin Psychopharmacol (2013) 33:199-205. doi:10.1097/JCP.0b013e3182825bfd.
34. McGeown WJ, Shanks MF, Venneri A. Prolonged cholinergic enrichment influences regional cortical activation in early Alzheimer's disease. Neuropsychiatr Dis Treat (2008) 4:465-76.
35. Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test: Adult Version Research Edition Manual. San Antonio, TX: The Psychological Corporation (1987).
36. Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test-Second Edition: Adult Version Manual. San Antonio, TX: The Psychological Corporation (2000).
37. Weschler D. Wechsler Memory Scale-Third Edition WMS-III Administration and Scoring Manual. San Antonio, TX: The Psychological Corporation (1997).
38. Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, et al. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci (2013) 5:11. doi:10.3389/fnagi.2013.00011.
39. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 43:2412-4. doi:10.1212/WNL.43.11.2412-a.
40. Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology (2006) 67:834-42. doi:10.1212/01.wnl.0000234032.77541.a2.
41. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 12:189-98. doi:10.1016/0022-3956(75)90026-6.
42. Cockrell JR, Folstein MF. Mini-mental state examination (MMSE). Psychopharmacol Bull (1988) 24:689-92.
43. Jurica P, Leitten C, Mattis S. Dementia Rating Scale-2. Lutz, FL: Psychological Assessment Resources, Inc (2001).
44. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol (1982) 37:323-9. doi:10.1093/geronj/37.3.323.
45. Squire LR, Wetzel CD, Slater PC. Memory complaint after electroconvulsive therapy: assessment with a new self-rating instrument. Biol Psychiatry (1979) 14:791-801.
46. Saykin AJ, Janssen RS, Sprehn GC, Kaplan JE, Spira TJ, O'Connor B. Longitudinal evaluation of neuropsychological function in homosexual men with HIV infection: 18-month follow-up. J Neuropsychiatry Clin Neurosci (1991) 3:286-98.
47. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med (1989) 19:1015-22. doi:10.1017/S0033291700005742.
48. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res (1982) 17:37-49. doi:10.1016/0022-3956(82)90033-4.
49. Rabin LA, Saykin AJ, Wishart HA, Nutter-Upham KE, Flashman LA, Pare N, et al. The Memory and Aging Telephone Screen: development and preliminary validation. Alzheimers Dement. (2007) 3:109-21. doi:10.1016/j.jalz.2007.02.002.
50. Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, Pare N, et al. Pharmacogenetic imaging in preclinical Alzheimer's disease: candidate genes and response to cholinergic enhancement in amnestic MCI. Thirty-Fourth Annual INS Meeting Abstracts. Cambridge: Cambridge University Press (2006) 55-6.
51. McDonald BC, Saykin AJ. fMRI Wada Test: prospects for presurgical mapping of language and memory. In: Faro SAM, Leng FB editors. Functional Neuroradiology: Principles and Clinical Applications. New York, NY: Springer (2012). p. 455-84.
52. Swick D, Knight RT. Contributions of prefrontal cortex to recognition memory: electrophysiological and behavioral evidence. Neuropsychology (1999) 13:155-70. doi:10.1037/0894-4105.13.2.155.
53. Wang Y, Mathews V, Kalnin A, Mosier K, Dunn D, Saykin A, et al. Short term exposure to a violent video game induces changes in frontolimbic circuitry in adolescents. Brain Imaging Behav (2009) 3:38-50. doi:10.1007/s11682-008-9058-8.
54. Gitelman DR, Penny WD, Ashburner J, Friston KJ. Modeling regional and psychophysiologic interactions in fMRI: the importance of hemodynamic deconvolution. Neuroimage (2003) 19:200-7. doi:10.1016/S1053-8119(03)00058-2.
55. Williams LM, Das P, Liddell BJ, Kemp AH, Rennie CJ, Gordon E. Mode of functional connectivity in amygdala pathways dissociates level of awareness for signals of fear. J Neurosci (2006) 26:9264-71. doi:10.1523/JNEUROSCI.1016-06.2006.
56. Foland LC, Altshuler LL, Bookheimer SY, Eisenberger N, Townsend J, Thompson PM. Evidence for deficient modulation of amygdala response by prefrontal cortex in bipolar mania. Psychiatry Res. (2008) 162:27-37. doi:10.1016/j.pscychresns.2007.04.007.
57. Brett M, Anton J.-L, Valabregue R, Poline J.-B. Region of interest analysis using an SPM toolbox. Presented at the 8th International Conference on Functional Mapping of the Human Brain, June 2-6, 2002. Sendai, Japan (2002).
58. Kelley WM, Miezin FM, McDermott KB, Buckner RL, Raichle ME, Cohen NJ, et al. Hemispheric specialization in human dorsal frontal cortex and medial temporal lobe for verbal and nonverbal memory encoding. Neuron (1998) 20:927-36. doi:10.1016/S0896-6273(00)80474-2.
59. Cabeza R. Hemispheric asymmetry reduction in older adults: the HAROLD model. Psychol Aging (2002) 17:85-100. doi:10.1037/0882-7974.17.1.85.
60. Whitehouse PJ, Price DL, Clark AW, Coyle JT, Delong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol (1981) 10:122-6. doi:10.1002/ana.410100203.
61. Green RC, Mesulam MM. Acetylcholinesterase fiber staining in the human hippocampus and parahippocampal gyrus. J Comp Neurol (1988) 273:488-99. doi:10.1002/cne.902730405.
62. Mesulam MM, Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J Comp Neurol (1988) 275:216-40. doi:10.1002/cne.902750205.
63. Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med (2002) 43:983-90.
64. Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, et al. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol (2002) 113:1241-8. doi:10.1016/S1388-2457(02)00110-4.
65. Chen X, Magnotta VA, DuffK, Boles Ponto LL, Schultz SK. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. J Neuropsychiatry Clin Neurosci (2006) 18:178-85. doi:10.1176/appi.neuropsych.18.2.178.